Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center.

With regard to PFS, those patients with longer GMI showed a trend toward a better median PFS when compared to those with GMI 0–1.33 (median PFS from trabectedin 10.2 months (95% CI 0.1–20.3) vs. five months (95% CI 3.1–6.9) ( p = 0.093)), as seen in Figure 4 . 3.

also in 53,322 other papers